Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

VX-950 enters phase II development for HCV

Dec. 9, 2005

Idenix outlines plans for valopicitabine phase III trials

Dec. 9, 2005

Recent patents disclose therapeutic agents for gastrointestinal disorders

Dec. 2, 2005

New antihepatitis C agents described in recent GSK patent

Nov. 30, 2005

Solvay suspends regulatory activities for cilansetron in U.S.

Nov. 30, 2005

Enrollment completed in phase III study of Entereg in postoperative ileus

Nov. 30, 2005

Preclinical efficacy reported for GI-5005, a therapeutic vaccine for chronic hepatitis C infection

Nov. 30, 2005

Results of natalizumab trials in Crohn's disease reported

Nov. 29, 2005

Novel P2Y receptor antagonist blocks experimental cirrhosis

Nov. 28, 2005

Theravance prepares and tests 5-HT4 receptor agonists for gastrointestinal disorders

Nov. 25, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...